Biogen (BIIB) Q1 2025 Earnings Call May 01, 2025 08:30 AM ET Speaker0 My name is Melinda, and I'll be your conference operator today. At this time, I'd like to welcome everyone to the Biogen First Quarter twenty twenty five Earnings Call and Business Update. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. Today's conference is being recorded. Thank you. I would now like to turn the conference over to Mr. Tim Power, ...

Phase 2b/3 Alzheimer’s trial enrolment expected to reach 100 this quarter, triggering an interim analysis 6 months laterSYDNEY, April 30, 2025 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) announces that its Alzheimer’s disease phase 2b/3 trial has now enrolled 60 participants and expects to reach 100 by the end of this quarter. That milestone will trigger an interim analysis of available trial data by an independent Data Monitoring Committee approximately 6 months later. Final results for the fu ...

Core Insights - Silo Pharma, Inc. has filed a patent application for its neurology drug SPC-14, aimed at treating Alzheimer's disease, which is exclusively licensed from Columbia University [1][3] Patent Details - The patent titled "Compositions and Methods for the Treatment of Alzheimer's Disease and Other Neurogenerative Disease" focuses on SPC-14's mechanism of action, targeting glutamate receptor NDMAR and serotonin 5-HT4 to alleviate cognitive and neuropsychiatric symptoms in Alzheimer's disease [2][4] Drug Development - Early pre-clinical studies indicate that SPC-14 has the potential to improve cognitive memory function [3] - The drug has shown efficacy in preclinical studies against luteinizing hormone (LH) stress, reducing learned helplessness, perseverative behavior, and hyponeophagia, which is a measure of anxiety [4] Company Overview - Silo Pharma is a developmental stage biopharmaceutical company that focuses on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system diseases [5] - The company's portfolio includes other innovative programs such as SPC-15 for PTSD and SP-26 for fibromyalgia and chronic pain, alongside preclinical assets targeting Alzheimer's disease and multiple sclerosis [5]

Core Viewpoint - The Davos Alzheimer's Collaborative (DAC) is launching the North African Dementia Registry (NADR) project in collaboration with PacBio, The American University in Cairo (AUC), and UCL to enhance understanding of Alzheimer's disease and dementia in diverse populations, particularly in North Africa [1][2][3] Group 1: Project Overview - The NADR is the first dementia-focused registry in North Africa, aiming to collect biosamples, conduct cognitive assessments, and perform digital phenotyping [2] - The initiative will create a comprehensive multi-omics dataset to explore genetic and environmental factors related to Alzheimer's disease [2][3] - Data generated will be accessible via the Alzheimer's Disease Data Initiative (ADDI) platform, promoting global research collaboration [3] Group 2: Technological Partnership - PacBio will provide its advanced long-read sequencing technology to generate high-quality genomic data essential for understanding the genetic landscape of Alzheimer's disease [2][3] - The collaboration aims to identify new diagnostic tools and therapeutic solutions for Alzheimer's disease [3] Group 3: Importance of Diversity in Research - The project addresses the underrepresentation of North African populations in dementia research, which is crucial given the region's genetic diversity [2][3] - Insights gained from this research are expected to inform locally relevant prevention and intervention strategies [3] Group 4: Broader Implications - DAC aims to extend global research efforts beyond traditional Western populations to include diverse populations in the Global South, where most Alzheimer's patients reside [4] - The initiative aligns with DAC's goal to implement health system solutions that are globally applicable and to promote brain health throughout the lifespan [4][5]

Core Insights - The Davos Alzheimer's Collaborative (DAC) has partnered with PacBio to support the North African Dementia Registry (NADR) project, aiming to enhance understanding of Alzheimer's disease in North African populations [1][2][3] - This initiative is the first dementia-focused registry in North Africa, addressing the underrepresentation of these populations in dementia research [2][3] - The collaboration will utilize PacBio's long-read sequencing technology to create a comprehensive multi-omics dataset, facilitating research into genetic and environmental factors related to Alzheimer's disease [2][3] Company Insights - PacBio is recognized for its advanced sequencing solutions, which are crucial for generating high-quality genomic data necessary for understanding the complex genetic landscape of Alzheimer's disease [3][12] - The partnership aligns with PacBio's commitment to enabling genomic discoveries that improve human health globally [3][12] - The data generated from this collaboration will be accessible through the Alzheimer's Disease Data Initiative (ADDI) platform, promoting further research and innovation in Alzheimer's disease [3][4] Industry Insights - The DAC initiative aims to extend global research efforts beyond traditional Western populations to include diverse populations in the Global South, where a significant number of Alzheimer's cases exist [4] - By 2050, it is projected that over 150 million families and half a billion people will be affected by dementia, highlighting the urgent need for effective research and intervention strategies [4] - The NADR project will enable the collection of biosamples, cognitive assessments, and digital phenotyping, which are essential for developing locally relevant prevention and intervention strategies [2][3]

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that Marwan Noel Sabbagh, MD, Professor of Neurology at Barrow Neurological Institute and Chairman ...

Core Insights - Roche Holdings AG presented new data on trontinemab at the AD/PD 2025 International Conference, highlighting its potential in Alzheimer's disease treatment and the Elecsys pTau181 plasma test's ability to rule out amyloid pathology [1][4]. Group 1: Trontinemab Study Results - The ongoing Phase 1b/2a Brainshuttle AD study of trontinemab showed dose-dependent rapid amyloid depletion from the brain [1]. - Preliminary results indicated that trontinemab reduced amyloid levels below the 24 centiloid threshold in 81% of participants (21 out of 26) in the 3.6 mg/kg dose group after 28 weeks [6]. - The study reported a favorable safety profile, with amyloid-related imaging abnormalities (ARIA-E) observed in less than 5% of participants, and only one case associated with mild symptoms [3]. Group 2: Elecsys pTau181 Plasma Test - Results from a multicenter study involving 604 participants demonstrated the Elecsys pTau181 plasma test's potential to accurately rule out amyloid pathology in individuals with cognitive impairment [4]. - Roche anticipates that the Elecsys pTau181 test will be available in Europe by late 2025, followed by the U.S. [4]. Group 3: Future Developments - Roche plans to initiate a Phase 3 program for trontinemab later this year [4]. - The company continues to reinforce its commitment to advancing research in Alzheimer's disease through ongoing studies and new testing methods [4]. Group 4: Market Reaction - Following the presentation of the new data, Roche's stock (RHHBY) closed lower by 4.37% to $37.65 [5].

InMed Pharmaceuticals (INM) Update / Briefing November 12, 2024 02:00 PM ET Speaker0 Hello, everyone. Thank you for attending today's Fierce Biotech webinar, Alzheimer's Outlook, The Next Step. I understand we have a great number of attendees on today's webinar, and I want to thank InMed Pharmaceuticals for sponsoring this presentation. My name is Phyllis Fearle, and I will be moderating today's conversation. But before we get started, here's a few quick housekeeping notes. You can access closed captions fr ...